Although the dorsal hippocampus (DH) and the ventral hippocampus (VH) densely innervate the nucleus accumbens, which mediates the expression of behavioural sensitization, the respective and specific contribution of DH and VH in the expression of behavioural sensitization to amphetamine has not been investigated. In the present study, we investigated how lidocaine infused in DH or VH modulated behavioural locomotor sensitization induced by repeated administration of systemic amphetamine. Rats, well habituated to their environmental conditions and experimental protocol, were given repeated administration of systemic amphetamine. Once behavioural sensitization was developed, rats were challenged with amphetamine and infused with saline (controls) or lidocaine into DH or VH. We found that reversible inhibition by lidocaine of DH, but not VH, blocks the expression of behavioural sensitization to amphetamine. Control animals injected with saline solution do express behavioural sensitization. Our results bring new insights on the role of the hippocampus complex in the expression of behavioural sensitization, indicating that, in individuals well habituated to the drug-associated context, DH but not VH would play a key role. The results provide experimental evidence for clinical studies in human addicts that have demonstrated that exposure to environmental stimuli associated with drug-taking behaviour elicits craving and can promote relapse, and further suggest that in drug abusers, once addiction has occurred, the contextual and spatial conditions that are associated with drug consumption may play a critical role in the maintenance of drug abuse.
Introduction
Behavioural sensitization in rodents refers to a progressive and persistent increase in the psychomotor activating and rewarding effects of drugs, which is seen when psychostimulant drugs are given repeatedly and intermittently (Kalivas and Stewart, 1991 ; Robinson and Becker, 1986 ; Robinson and Berridge, 1993) . This is a well-characterized phenomenon that has received considerable attention because of its proposed relevance to drug addiction and psychosis. Particularly, but not only, behavioural sensitization involves alterations in neurotransmission within the dopaminergic mesoaccumbens system, which originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens (NAc). While alterations within the VTA appear to initiate sensitization, i.e. its development, alterations within the NAc appear to mediate the expression of sensitization (Cador et al., 1995 ; Kalivas and Weber, 1988 ; Paulson and Robinson, 1991) . Although the mesoaccumbens dopamine pathway is strongly involved in behavioural sensitization to psychostimulant drugs, other neurotransmitters, such as excitatory amino acids, may play a key role in this process since dopamine and glutamate are well known for modulating each other's neurotransmitter release and locomotor activity in the mesoaccumbens and nigrostriatal pathways (David et al., 2005) . Accordingly, depending on the subtype of receptor considered, co-administration of glutamate receptor antagonists with psychostimulant drugs can prevent the development and/or the expression of behavioural sensitization to psychostimulants (Karler et al., 1989 (Karler et al., , 1991 Wolf et al., 1995) . This has led to the suggestion that brain structures that provide significant excitatory amino-acid innervation of either the VTA and/or the NAc may play a key role in the development and/or the expression of behavioural sensitization to psychostimulant drugs.
Drug-induced changes in dopaminergic and glutamatergic neurotransmission progressively result in complex cellular and molecular neuroadaptive processes. Interestingly, both the dorsal hippocampus (DH) and the ventral hippocampus (VH) innervate, through glutamatergic neurons, the dopaminergic mesoaccumbens pathway (Groenewegen et al., 1987 ; Kelley and Domesick, 1982) . Taken together with the possible contribution of excitatory amino acids in the development and/or the expression of behavioural sensitization, these anatomical findings suggest that the hippocampal formation, including DH and VH, could be an interesting target that might contribute to some of the mechanisms underlying addiction to psychostimulant drugs, such as cocaine and amphetamine and its derivatives.
The contribution of the hippocampus complex to behavioural responses to acute and chronic amphetamine has been investigated using lesion techniques and pharmacology, but no general consensus has been established depending on the area of the hippocampus complex considered. For instance, while previous studies have reported that massive lesion of the hippocampus or the fimbria-fornix, a subcortical area that mediates most of the hippocampal output signals, increased hyperlocomotion induced by acute amphetamine (Coutureau et al., 2000 ; Mittlemann et al., 1998 ; Schaub et al., 1997 ; Wilkinson et al., 1993 ; Wolf et al., 1995) , others have found a reduction of hyperlocomotion to acute amphetamine following lesion of the hippocampus or the fimbria-fornix (Burns et al., 1993 ; White et al., 2006) or no effect (Bannerman et al., 2003 ; Bardgett and Henry, 1999) . Similarly, discrete excitotoxic lesion or inhibition of DH by lidocaine has been reported to increase hyperlocomotion induced by acute amphetamine, whereas inhibition of VH has been shown to block it (Burns et al., 1993 ; Caine et al., 2001 ; White et al., 2006) , thereby suggesting that DH and VH may exert respectively, in normal conditions, an inhibitory and a facilitatory action on the motor-activating properties of amphetamine. However, others have found that electrolytic lesion of VH potentiated rather than reduced hyperlocomotion to acute amphetamine (Riegert et al., 2004) . The contribution of the hippocampus or subparts of itmainly VH because of its role in emotional responses and fear and anxiety-related processes (Amaral and Witter, 1995 ; Kjelstrup et al., 2002) -in behavioural sensitization to psychostimulant drugs has also been studied. However, as reported for acute amphetamine, no general consensus has been established. While studies have reported that lesion of the hippocampus or the fimbria-fornix blocked the development, but not the expression, of behavioural sensitization (Coutureau et al., 2000 ; Yoshikawa et al., 1991 Yoshikawa et al., , 1993 , others have found no effect (Bannerman et al., 2003 ; Browman et al., 1996 ; Wolf et al., 1995) .
Surprisingly from a clinical perspective, and to the best of our knowledge, the respective and specific contribution of DH and VH in the expression of behavioural sensitization to amphetamine has not yet been investigated, although DH and VH densely innervate the NAc, which is the site that mediates the expression of behavioural sensitization. In the present study, we investigated how reversible inhibition of DH or VH modulates the expression of behavioural sensitization to amphetamine. To inhibit DH and VH and to avoid non-physiological irreversible lesions, we used lidocaine, a sodium channel blocker with local anaesthetic properties, which allows preservation of anatomical integrity and thereby within-group comparison of data.
Methods

Subjects
All animal-use procedures were in accordance with the Declaration of Helsinki and the French legislation for the use of animals in biomedical experimentation. Male Sprague-Dawley rats (Janvier, Le Genest-St-Isle, France) weighing 225-250 g were used. They were housed socially by groups of six, at 21¡0.5 xC, in Perspex home cages with free access to food and water, for at least 3 d before being used for surgery. Light was maintained on a light-dark cycle, with lights on from 20:00 to 08:00 hours. All experiments were performed between 10:30 and 15:30 hours, during the dark period.
Surgical procedures
On the day of surgery, rats were anaesthetized by an intraperitoneal injection of 30 mg/kg pentobarbital. Then, they were mounted on a stereotaxic apparatus with the incisor bar set 3.9 mm below the horizontal zero. They were implanted with chronic bilateral stainless-steel guide cannulae (21-gauge), 1 mm above the drug target injection site in DH (A x2.8, L 1.6, V x3.4 from Bregma) or VH (A x5.6, L 4.6, V x8.0 from Bregma), according to the rat brain atlas of Paxinos and Watson (1998) . The guide cannulae of length 10 mm (DH) or 12 mm (VH) were anchored to the skull with two stainless-steel screws and dental cement. Stainless-steel wire stylets were inserted into the guide cannulae to prevent occlusion. After surgery, the animals were housed in individual Perspex home cages with free access to food and water, and allowed to recover for at least 5 d before being subjected to any behavioural investigation and/or pharmacological treatment.
Drug treatment and injection procedure
Drugs were purchased from Sigma-Aldrich (SaintQuentin-Fallavier, France) and dissolved in saline solution. D-amphetamine sulphate (1 mg/kg) was administered intraperitoneally in 1 ml. Lidocaine (100 mg/side) was infused in 1 ml/side at the rate of 0.3 ml/min into DH or VH to a depth of 1 mm below the guide cannula tips, using 30-gauge injection cannulae of length 11 mm (DH) or 13 mm (VH) connected via microtubing to microsyringes (ref. MS10U, Ito, Fuji, Japan) mounted on a microdrive pump (ref. PHD2000, Harvard Apparatus, MA, USA) ; 60 s after the end of the infusion period, the injection cannulae were removed. Control animals were given 1 ml/side saline solution into DH or VH. The doses of lidocaine and amphetamine were chosen on the basis of previous studies (David et al., 2006 ; Kantak et al., 2002) . Although lidocaine is sometimes believed to have only short-term effects of about 20 min duration, there is evidence from previous investigations, and as found in the present study, that it can produce longer inhibition in the brain of at least of 90 min duration (Lomber, 1999 ; Rouillon et al., 2007) .
Experimental protocols
Acute amphetamine administration
On day 1, the acute-DH group (n=8) and the acute-VH group (n=7) were given systemic saline injection and saline infusion into DH or VH. On day 8, both groups were given lidocaine infusion into DH or VH and systemic saline injection. On day 15, all rats were given saline into DH or VH and systemic amphetamine. On day 22, both the acute-DH group and the acute-VH group were given systemic amphetamine and a lidocaine infusion into DH or VH (see Figure 1a) .
Behavioural sensitization to amphetamine
The general consensus is that the incentive properties of psychostimulant drugs influence behaviour by acting both on contextual and spatial memory, and intrinsic affective and emotional memory (Bannerman et al., 1999 ; White, 1996) . On the other hand, environmental novelty is known to enhance the behaviouralactivating effects of amphetamine (Badiani et al., 1999) . Thus, in order to avoid this phenomenon, which may influence one type of memory compared to another, rats were very well habituated to their environmental conditions and experimental protocol as illustrated in Figure 1b .
On days 1 and 2, all groups of animals including DH-control group (n=6), DH-treated group (n=6), VH-control group (n=5), and VH-treated group (n=6) were given one daily systemic injection of saline solution and virtual bilateral infusion into DH or VH that consisted of introducing 6-mm-long cannulae connected to microtubing in the guide cannulae for a 5-min period. On day 3, all groups were given one further systemic injection of saline solution and actual bilateral infusion of saline solution into DH or VH ; locomotor activity was then immediately recorded. From days 4 to 6, the animals were allowed to recover for 3 d in the animal colony. On day 7, rats were given systemic injection of amphetamine and bilateral infusion of saline solution into DH or VH, and locomotor activity was recorded. On days 8 and 9, rats were brought from the animal colony to the activity room, but not to the activity cages, to receive one daily systemic injection of amphetamine. After 15-20 min, the animals were returned to the animal colony without being assessed for locomotor activity. From days 10 to 12, the animals were allowed to recover in the animal colony. On day 13, all groups of animals were given one systemic challenge injection of amphetamine and bilateral infusion of either saline solution (DH-and VH-control groups) or lidocaine (DH-and VH-treated groups) into DH or VH ; the animals' locomotor activity was then immediately recorded. All injections were performed in the activity room.
Measurement of locomotor activity
One week before the experimental protocol started on day 1, the animals were handled for virtual intraperitoneal injection and virtual infusion in DH or VH, and placed individually at least twice for several hours in the activity cages to familiarize them with this environment. On the test days (days 1, 8, 15, 22 for the acute protocol ; days 3, 7, 13 for the sensitization protocol), the animals were placed in the activity cages for 60 min. Rats were then injected with either saline or drug as indicated above, and placed in the activity cages, and locomotor activity was recorded for 90 min. Locomotor activity was quantified using a bank of eight individual activity cages measuring 30r20r 20 cm, equipped with two parallel horizontal infrared beams, located 3 cm above the floor across the long axis of the cage (Imetronic, Pessac, France). Beam interruptions were detected, and recorded over 10-min intervals on a PC computer.
Histology
Rats were killed by intracardiac infusion of sodium pentobarbital under halothane anaesthesia. The skull, including the brain cannula, was quickly removed and post-fixed in a formol solution for at least 1 wk. Brain coronal sections (120 mm) were cut and mounted on gelatinized slides, stained with Cresyl Violet (1 %), dehydrated with serial alcohol and cleared with xylene, and coverslipped with DPX (Fluka, Paris, France). The placements of the cannula tips were checked using a bench microscope.
Data presentation and statistical analysis
Locomotor activity scores are expressed as mean¡ S.E.M. They were analysed using non-parametric statistics, since, as stated by Siegel and Castellan (1988) , there is no alternative for a small sample size other than using a non-parametric statistical test unless the nature of the population distribution is known exactly. Accordingly, within-group comparisons were analysed using Friedman's non-parametric ANOVA test for more than two groups for paired series. Following a significant F value, post-hoc comparisons were further performed using Wilcoxon's signed-ranks paired t test, which is the non-parametric version of the t test to be used in the case of two related (paired) samples or repeated measurements on a single and small On day 1 both groups [acute dorsal hippocampus (DH) and acute ventral hippocampus (VH)] received a systemic saline injection (S) and a saline infusion into DH or VH. One week later, they were given a lidocaine infusion (L) into DH or VH following a systemic saline injection. On day 15 animals received a systemic amphetamine injection (A) followed by a saline infusion into either DH or VH. Finally on day 22, both groups were given a lidocaine infusion into DH or VH following a systemic amphetamine injection. An interval of 1 wk was observed between each pharmacological treatment, during which the animals were allowed to rest in the animal colony. Arrows indicate the days the rats' locomotor activity was recorded. (b) Protocol of behavioural sensitization to amphetamine. On days 1 and 2, all groups including DH-and VH-control groups and DH-and VH-treated groups were given one daily systemic injection of saline solution (S) and virtual bilateral infusion (V) into DH or VH. On day 3, all groups were given one further systemic injection of saline solution and actual bilateral infusion of saline solution into DH or VH. On day 7, rats were given one systemic injection of amphetamine (A) and bilateral infusion of saline solution into DH or VH. On days 8 and 9, rats were given additional daily systemic injections of amphetamine. Finally, on day 13, rats were given one systemic challenge injection of amphetamine and bilateral infusion of either saline solution (DH-and VH-control groups) or lidocaine (DH-and VH-treated groups) into DH or VH. Arrows indicate the days the rats' locomotor activity was recorded.
sample. In the sensitization protocol, between-group comparisons were performed using the KruskalWallis non-parametric ANOVA test for unpaired series. Following a significant H value, post-hoc comparisons of two independent samples were performed using the Mann-Whitney U test.
Results
Histology
The placement of the cannula tips into DH and VH, were checked as described above. Data from rats with injection sites outside DH or VH (n=18) were excluded from the data collection and subsequent statistical analysis. Figure 2 illustrates the location sites of the cannula tips placed in DH and VH. Figure 3 ). This agrees with previous data (Bardgett and Henry, 1999 ; Rouillon et al., 2007 ; White et al., 2006) . In contrast with these findings, Flicker and Geyer (1982) reported that infusion of lidocaine into DH reduced basal locomotor activity. Differences in the experimental procedures and protocols may explain the discrepancies between these studies. For instance, in contrast to the study of Flicker and Geyer (1982) where lidocaine was infused continuously at a rate of 0.0025 ml/min over a 40-min experimental session (1 ml of total volume), lidocaine was infused much more rapidly in the present study (1 ml at a rate of 0.3 ml/min) and those by Rouillon et al. (2007) (1 ml at a rate of 0.3 ml/min) and Bardgett and Henry (1999) (1 ml at a rate of 0.5 ml/min). Analysis of locomotor activity following systemic injection of acute amphetamine and bilateral infusion of saline solution in DH and VH produced a significant timertreatment effect in both the acute-DH group and the acute-VH group (acute-DH group : F 8,112 =64.222, p<0.0001 ; acute-VH group : F 8,96 = 55.254, p<0.0001), indicating a change in locomotor activity. Post-hoc statistical analysis revealed that total scores of locomotor activity were increased compared to total scores of locomotor activity recorded after systemic saline injection (acute-DH group : Z= x2.521, p<0.02, Figure 3a ; acute-VH group :
Z=x2.366, p<0.02, Figure 3b ). Bilateral infusion of lidocaine into DH or VH produced a significant treatmentrtime effect in both groups (acute-DH group : F 8,112 =18, p<0.0001 ; acute-VH group : F 8,96 = 13.349, p<0.0001) indicating a change in locomotor activity induced by systemic injection of amphetamine. Post-hoc analysis of locomotor activity revealed that total scores of locomotor activity produced by systemic amphetamine were increased when rats were infused with lidocaine into DH (Z=x2.240, p<0.05, Figure 3a ) and into VH (Z=x2.197, p<0.05, Figure 3b ). Effect of lidocaine infusion into DH on the expression of behavioural sensitization to amphetamine Figure 4 illustrates the effect of lidocaine infused into DH on the expression of behavioural sensitization to amphetamine. As expected, analysis of locomotor activity following injection of acute amphetamine and bilateral infusion of saline solution in DH produced a significant timertreatment effect in both DH-control group (F 8,80 =46.296, p<0.0001) and DH-treated group (F 8,80 =54, p<0.0001), indicating a change in locomotor activity. Post-hoc statistical analysis revealed that total scores of locomotor activity were increased compared to those recorded after systemic saline injection (DH-control group : Z=x2.201, p<0.05 ; DH-treated group : Z=x2.201, p<0.05). In DH-control group, repeated administration of amphetamine produced a significant timertreatment effect (F 8,80 =39.185, p<0.0001), reflecting a change in the locomotoractivating properties of amphetamine. Post-hoc statistical analysis revealed that total scores of locomotor activity following repeated administration of amphetamine were increased compared to acute amphetamine (Z=x2.201, p<0.05, Figure 4a ). In contrast, in rats infused with lidocaine into DH, repeated injection of amphetamine produced no significant timertreatment effect (F 8,80 =3.630, n.s., Figure  4b ), indicating that lidocaine infusion in DH blocked the expression of behavioural sensitization to amphetamine.
Between-group comparisons were also performed. Data analysis revealed no significant timertreatment effect between DH-control group and DH-treated group on day 3 (H=1690, n.s.) and day 7 (H=1323.5, n.s.). In contrast, between-group comparison showed a significant timertreatment effect between DHcontrol group and DH-treated group on day 13 (H= 2309.5, p<0.0001). Post-hoc analysis revealed total scores of locomotor activity were higher in the DHcontrol group than in the DH-treated group (U=5, p<0.05). In agreement with the within-group analysis of data performed above, this confirmed that lidocaine infusion into DH did block the expression of behavioural sensitization to amphetamine, as also illustrated by the value of the 'ratio of sensitization ', i.e. , and the ventral hippocampus (VH), on basal and amphetamine-induced locomotion. Bilateral infusion of lidocaine (100 mg/side) into (a) DH or (b) VH had no effect on basal locomotion but further potentiates the hyperlocomotion observed after acute systemic injection of amphetamine (1 mg/kg . ml). (a, b) Rats were placed in the photocell activity cages for 60 min before being subjected to drug administration, and then recorded for 90 min. The ordinates give the mean number of counts in 10-min periods. Error bars were deleted for clarity of presentation. The inset represents the total photocell counts¡S.E.M. during the 90-min period of testing following drug administration. * p<0.02 vs. day 1 ; # p<0.05 vs. day 15.
DH-treated group (this ratio corresponds to the score of locomotor activity in response to repeated injection of amphetamine divided by the score of locomotor activity in response to acute amphetamine). Figure 5 illustrates the effect of lidocaine infused into VH, compared to saline, on the expression of behavioural sensitization to amphetamine. Analysis of locomotor activity following injection of acute amphetamine and bilateral infusion of saline solution into VH produced a significant timertreatment effect in both VH-control group (F 8,64 =33.8, p<0.0001) and VH-treated group (F 8,80 =39.185, p<0.0001), indicating a change in locomotor activity. Post-hoc statistical analysis revealed that total scores of locomotor activity following injection of acute amphetamine were increased compared to total scores of locomotor activity recorded after systemic saline administration (VHcontrol group : Z=x2.023, p<0.05 ; VH-treated group : Z=x2.201, p<0.05, Figure 5 ). Repeated administration of amphetamine produced a significant timertreatment effect both in VH-control group (F 8,64 =21.356, p<0.0001) and VH-treated group (F 8,80 =42.667, p<0.0001), reflecting a change in the locomotor-activating properties of amphetamine. Post-hoc statistical analysis revealed that total scores of locomotor activity following repeated administration of amphetamine were increased compared to total scores of locomotor activity induced by an acute injection of amphetamine both in VH-control group (Z=x2.023, p<0.05, Figure 5a ) and VH-treated group /kg) , systemic injection of acute amphetamine (1 mg/kg . ml) significantly increases locomotor activity in the DH-control group. Repeated injection of systemic amphetamine led to a significant increase of the locomotor-activating properties of amphetamine in the DH-control group infused with saline into DH. (b) Systemic injection of acute amphetamine significantly increases locomotor activity in the DH-treated group. Repeated administration of systemic amphetamine led to no significant increase of the locomotor-activating properties of amphetamine in the DH-treated group, indicating that infusion of lidocaine (100 mg/side) into DH blocked the expression of behavioural sensitization to amphetamine. (a, b) Rats were placed in the photocell activity cages for 60 min ; the rats' locomotor activity was then recorded for 90 min. The ordinate gives the mean number of counts in 10-min periods. Error bars were deleted for clarity of presentation. The inset represents the total photocell counts¡S.E.M. during the 90 min period of testing following drug administration. Within-group comparisons : * p<0.05 vs. day 3 ; # p<0.05 vs. day 7. Between-group comparisons : # p<0.05.
Effect of lidocaine infusion into VH on the expression of behavioural sensitization to amphetamine
(Z=x2.201, p<0.05, Figure 5b ), thereby indicating that infusion of lidocaine into VH did not block the expression of behavioural sensitization to amphetamine.
Between-group comparisons were also performed. Data analysis revealed no significant timertreatment effect between VH-control group and VH-treated group on day 3 (H=1154, n.s.) and day 7 (H=1134.5, n.s.). Between-group comparison produced a significant timertreatment effect between VH-control group and VH-treated group on day 13 (H=897, p<0.05), but post-hoc analysis on total scores of locomotor activity revealed no significant difference between VHcontrol group and VH-treated group (U=10, n.s.). In agreement with the within-group analysis of data performed above, this confirmed that infusion of lidocaine in VH did not block the expression of behavioural sensitization to amphetamine, as also illustrated by the value of the 'ratio of sensitization ', i.e. 1.71¡ 0.13 in VH-control group and 1.87¡0.15 in VH-treated group. Interestingly, it has to be emphasized that these values are not far from that obtained in the DH-control group, which also exhibited sensitization in response to repeated injection of amphetamine.
Discussion
The aim of the present study was to specify the role of DH and VH on the locomotor-activating properties of acute and chronic (sensitization) amphetamine. Our /kg) , systemic injection of acute amphetamine (1 mg/kg . ml) significantly increases locomotor activity in the VH-control group. Repeated injection of systemic amphetamine led to a significant increase of the locomotor-activating properties of amphetamine in the VH-control group infused with saline into VH. (b) Compared to saline (1 ml/kg), systemic injection of acute amphetamine (1 mg/kg . ml) significantly increases locomotor activity in the VH-treated group. Repeated administration of systemic amphetamine led to a significant increase of the locomotor-activating properties of amphetamine in the VH-treated group, indicating that infusion of lidocaine (100 mg/side) into VH did not block the expression of sensitization to amphetamine. (a, b) Rats were placed in the photocell activity cages for 60 min ; the rats' locomotor activity was then recorded for 90-min. The ordinate gives the mean number of counts in 10-min periods. Error bars were deleted for clarity of presentation. The inset represents the total photocell counts¡S.E.M. during the 90-min period of testing following drug administration. Within-group comparisons : * p<0.05 vs. day 3 ; # p<0.05 vs. day 7. Between-group comparisons revealed no significant difference. experiments indicated that reversible inhibition induced by lidocaine of DH and VH potentiates the increase in locomotor activity induced by acute amphetamine. In addition, we also found that inactivation by lidocaine of DH, but not VH, blocks the expression of behavioural sensitization to amphetamine. These results indicate that under lidocaine-free conditions (i) DH and VH would exert an inhibitory action on the locomotor-activating properties of acute amphetamine ; (ii) DH, but not VH, would have a facilitating and necessary action on the expression of behavioural sensitization induced by repeated administration of amphetamine. Taken together, our findings indicate that the inhibitory role of DH in acute amphetamine switches towards a facilitating role in chronic amphetamine, and further suggest that VH may not play a key role in chronic amphetamine.
The role of DH and VH in locomotor activity produced by acute amphetamine
Our findings indicate that DH and VH would exert a tonic inhibitory action on locomotor activity induced by acute amphetamine, and further suggest that both structures may act as neural breakers in attempting to limit the psychostimulant effects of acute amphetamine in naive rats. As far as DH is concerned, our findings are in line with previous data that have indicated that the hippocampus is a source of inhibitory control of the accumbal dopaminergic tonus (Caine et al., 2001 ; Riegert et al., 2004 ; Schaub et al., 1997 ; Wilkinson et al., 1993) . In contrast, the role of VH appears more controversial, since previous studies have reported either a facilitating action (Burns et al., 1993 ; Caine et al., 2001 ; White et al., 2006) or, in agreement with our findings, an inhibitory control of VH on locomotor activity produced by acute amphetamine (Riegert et al., 2004) . This discrepancy regarding the role of VH may result from the different techniques used. While the technique of electrolytic lesion used by Riegert et al. (2004) affected both the subicular neurons and the fibres of passage within VH, the injection of quinolinic acid performed by Burns et al. (1993) and Caine et al. (2001) only damaged the subicular neurons without altering the fibres of passage within VH. In the present study, based on our results, we assume, with little doubt, that focal administration of lidocaine into VH would have affected the firing activity of both the subicular neurons and the fibres of passage within VH, thereby leading to a similar effect than that found by Riegert and colleagues (2004) .
The role of DH and VH in the expression of behavioural sensitization to amphetamine For the first time, to the best of our knowledge, we found that reversible inhibition induced by lidocaine, of DH, but not VH, blocks the expression of behavioural sensitization to amphetamine. This suggests that in well-habituated rats, DH -known to play a major role in spatial learning and conditioning (Bannerman et al., 1999 (Bannerman et al., , 2003 Moser et al., 1993 ) -would have a necessary role for the expression of behavioural sensitization to amphetamine ; in contrast, VH which is believed to be more allied to emotional responses (Amaral and Witter, 1995 ; Ferbinteanu and McDonald, 2000 ; Kjelstrup et al., 2002) , would not be required for the expression of behavioural sensitization.
The general consensus is that the incentive properties of psychostimulant drugs influence behaviour through contextual and pavlovian conditioning and stressful experience (Anagnostaras and Robinson, 1996 ; Browman et al., 1998 ; Sarnyai, 1998 ; Stewart and Badiani, 1993) by acting on learning and memory systems (O'Brien et al., 1992 ; White, 1996) . Among the multiple memory systems, the hippocampal formation mediates contextual and spatial memory mainly through DH that plays a key role in the storage of external cues and experiences, as well as intrinsic affective, emotional and fear-related responses through VH (Amaral and Witter, 1995 ; Bannerman et al., 1999 Bannerman et al., , 2003 Ferbinteanu and McDonald, 2000 ; Kjelstrup et al., 2002 ; Moser et al., 1993 ; White, 1996) . Taken together with our findings, this suggests that DH and the contextual and spatial conditions that are associated with drug administration would play a critical role in the expression of behavioural sensitization. This is in good agreement with previous studies that have shown that animals do not express sensitization when the amphetamine challenge is performed in a context that has never been paired with drug administration (Anagnostaras et al., 2002) . Reciprocally, given our protocol of habituation, the amount of stress that the animals experienced might have been reduced considerably ; this may have led to the lack of apparent contribution of VH in behavioural sensitization in the present study. However, the lack of effect of VH inactivation on the expression of behavioural sensitization may result from the fact that in the present study the animals did not experienced enough pairings between amphetamine administration and the activity cages. If so, it is possible that if all drug pairings were done in the activity cages, inactivation of VH would have been effective as well. In that way, it has been reported that VH does support some limited acquisition of spatial information and navigation, albeit less efficiently than more dorsal regions of the hippocampus complex (Ferbinteanu and McDonald, 2000 ; Kjelstrup et al., 2002) . Nevertheless, although it is generally admitted that the apparatus cues constitute the main and primary stimuli related to spatial conditioning and behavioural sensitization, other stimuli such as the injection procedure may also play a role in the total context (Pert et al., 1990) .
Alternatively, we propose that DH and VH switches may be regarded in line with a recent and elegant neurocognitive perspective of addiction, which suggests that the first experience of drug abuse -and then after addiction -can be viewed as the product of an imbalance between two separate, but interacting, neural systems that control decision making : an impulsive, amygdala (and other ventral brain areas that link the features of a stimulus to its affective and emotional attributes) system for signalling immediate prospects, and a reflective, prefrontal cortex-dorsal hippocampus system for signalling future prospects (Bechara, 2005) . In this perspective, the decision to use or not to use drugs would depend on the balance between the impulsive system and the reflective system that control the NAc, so that in individuals vulnerable to addiction the processes driven by the prefrontal cortex-hippocampus reflective system that enables one to inhibit actions elicited by the amygdala-ventral impulsive system would be dysfunctional because of genetic and/or environmentally induced reasons. Accordingly, in the present study, at the first time amphetamine is administered, both DH and VH may generate inhibitory signals in order to reduce or to block this unusual amphetamine immediate experience, as assessed by the facilitating action on the locomotor response to acute amphetamine of lidocaine injection in DH or VH. Then, once sensitization occurs, the contribution of DH and VH would switch towards a facilitating and a passive role.
Possible neural mechanisms underlying the role of DH and VH in locomotor activity induced by acute and repeated amphetamine
The hippocampus complex densely innervates the NAc, which is believed to be the site that mediates behavioural sensitization. The core of the NAc is believed to mediate behavioural locomotor activation, whereas the shell of the NAc is thought to contribute to reward and emotion (Sellings and Clarke, 2003) . In rodents, glutamatergic neurons from DH innervate the NAc core through the dorsal subiculum, but also send massive projections to the VH and the cortex ; in contrast, VH, including the CA1 and subicular areas, densely innervates the NAc shell, and to a lesser extent the NAc core (Brog et al., 1993 ; Ferbinteanu and McDonald, 2001 ; Groenewegen et al., 1987 ; Kelley and Domesick, 1982) , as well as prefrontal cortex neurons that have been identified to innervate the core of the NAc (Jay et al., 1995 ; Thierry et al., 2000) . Within DH, the projection field from the dorsal subiculum to the core is substantially more rostral and lateral than the region of DH that was inactivated by lidocaine in the present study. Therefore, it can be suggested that inactivation of DH by lidocaine did not alter the monosynaptic pathways that project from the hippocampus complex. That being so, it is likely that the effects observed following inactivation of DH may have resulted from an alteration of intra-hippocampic processing (Wilkinson et al., 1993) . Nevertheless, either directly or indirectly, such alterations in glutamatergic neurotransmission originating from the hippocampus complex will result in significant changes in dopamine release (Peleg-Raibstein and Feldon, 2006) and post-synaptic inputs to striatal projection neurons (Rouillon et al., 2007) in the NAc. This will result in fine hyperlocomotion and behavioural sensitization.
Conclusion
Our results bring new insights into the role of the hippocampus complex in the expression of behavioural sensitization, indicating that in individuals well habituated to the drug-associated context, DH, but not VH, would play a key role. They provide experimental evidence for clinical studies in human addicts that have demonstrated that exposure to environmental stimuli associated with drug-taking behaviour elicits craving and can promote relapse (O'Brien et al., 1992) , and further suggest that in drug abusers, once addiction has occurred, the contextual and spatial conditions that are associated with drug consumption may play a critical role in the maintenance of drug abuse that progressively lead the drug user to adopt self-destructive behaviours and habits. This emphasizes that the cognitive and contextual aspects that are involved in drug addiction must be taken into account to adapt psychotherapy associated with pharmacological treatment in human addicts. Pharmaceuticals (Canada). C.R. was supported by a doctoral fellowship from the Conseil Régional de Basse Normandie.
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